Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease
- The FDA has signed off Caladrius Bioscience Inc's (NASDAQ: CLBS) investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD").
- The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the next several months.
- Price Action: CLBS shares are up 0.06% at $1.56 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Kidney DiseasesBiotech News Penny Stocks Health Care FDA General
